Eli Lilly: Oral GLP-1 Foundayo Demonstrates Cardiovascular Safety, Sustained A1C Reduction And Weight Loss In Type 2 Diabetes Study

Shows 53% Lower Cardiovascular Death Risk And 57% Lower All-Cause Death Risk Versus Insulin Glargine - ACHIEVE-4 Shows 16% Lower MACE-4 Risk And 23% Lower MACE-3 Risk Versus Insulin Glargine - MACE Risk Met Non-Inferiority Threshold Versus Insulin Glargine